BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17625938)

  • 1. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses.
    Wilken B; Baumann M; Bien CG; Hero B; Rostasy K; Hanefeld F
    Eur J Paediatr Neurol; 2008 Jan; 12(1):51-5. PubMed ID: 17625938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome.
    Rostásy K; Wilken B; Baumann M; Müller-Deile K; Bieber I; Gärtner J; Möller P; Angelini P; Hero B
    Neuropediatrics; 2006 Oct; 37(5):291-5. PubMed ID: 17236108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.
    Ertle F; Behnisch W; Al Mulla NA; Bessisso M; Rating D; Mechtersheimer G; Hero B; Kulozik AE
    Pediatr Blood Cancer; 2008 Mar; 50(3):683-7. PubMed ID: 17226843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.
    Burke MJ; Cohn SL
    Pediatr Blood Cancer; 2008 Mar; 50(3):679-80. PubMed ID: 16900484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.
    Mitchell WG; Davalos-Gonzalez Y; Brumm VL; Aller SK; Burger E; Turkel SB; Borchert MS; Hollar S; Padilla S
    Pediatrics; 2002 Jan; 109(1):86-98. PubMed ID: 11773546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroblastoma found in a 4-year-old after rituximab therapy for opsoclonus-myoclonus.
    Chang BH; Koch T; Hopkins K; Malempati S
    Pediatr Neurol; 2006 Sep; 35(3):213-5. PubMed ID: 16939863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome.
    Kyrieleis HA; Levtchenko EN; Wetzels JF
    Am J Kidney Dis; 2007 May; 49(5):592-7. PubMed ID: 17472840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
    Leen WG; Weemaes CM; Verbeek MM; Willemsen MA; Rotteveel JJ
    Pediatr Neurol; 2008 Sep; 39(3):213-7. PubMed ID: 18725071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome.
    Tate ED; Allison TJ; Pranzatelli MR; Verhulst SJ
    J Pediatr Oncol Nurs; 2005; 22(1):8-19. PubMed ID: 15574722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis.
    Armstrong MB; Robertson PL; Castle VP
    Pediatr Neurol; 2005 Nov; 33(5):365-7. PubMed ID: 16243225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Hoefgen ER; Swan JA; Colliver JA
    Cytokine; 2008 Oct; 44(1):26-32. PubMed ID: 18675552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia.
    Mitchell WG; Brumm VL; Azen CG; Patterson KE; Aller SK; Rodriguez J
    Pediatrics; 2005 Oct; 116(4):901-7. PubMed ID: 16199699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.
    Matthay KK; Blaes F; Hero B; Plantaz D; De Alarcon P; Mitchell WG; Pike M; Pistoia V
    Cancer Lett; 2005 Oct; 228(1-2):275-82. PubMed ID: 15922508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).
    Krasenbrink I; Fühlhuber V; Juhasz-Boess I; Stolz E; Hahn A; Kaps M; Hero B; Blaes F
    Neuropediatrics; 2007 Jun; 38(3):114-6. PubMed ID: 17985258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Opsoclonus-Myoclonus Syndrome in Patients of the Largest Pediatric Hospital in Latin America.
    Zeny MS; do Valle DA; Santos MLSF; Bara TS; Cordeiro ML
    Pediatr Neurol; 2024 May; 154():9-14. PubMed ID: 38430891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Opsoclonus-myoclonus syndrome].
    Arroyo HA; Tringler N
    Medicina (B Aires); 2009; 69(1 Pt 1):64-70. PubMed ID: 19240003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opsoclonus-myoclonus syndrome: a clinicopathological confrontation.
    Baets J; Pals P; Bergmans B; Foncke E; Smets K; Hauman H; Vanderwegen L; Cras P
    Acta Neurol Belg; 2006 Sep; 106(3):142-6. PubMed ID: 17091618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies in childhood opsoclonus-myoclonus syndrome.
    Blaes F; Pike MG; Lang B
    J Neuroimmunol; 2008 Sep; 201-202():221-6. PubMed ID: 18687475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New autoantibodies in pediatric opsoclonus myoclonus syndrome.
    Kirsten A; Beck S; Fühlhuber V; Kaps M; Kreutz T; Korfei M; Schmitt S; Preissner KT; Blaes F
    Ann N Y Acad Sci; 2007 Sep; 1110():256-60. PubMed ID: 17911440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
    Raffaghello L; Conte M; De Grandis E; Pistoia V
    Eur J Paediatr Neurol; 2009 May; 13(3):219-23. PubMed ID: 18571942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.